<DOC>
	<DOCNO>NCT00356421</DOCNO>
	<brief_summary>To compare efficacy safety Exubera® v Humalog patient type 1 diabetes mellitus</brief_summary>
	<brief_title>A Clinical Trial Comparing Efficacy Safety Exubera® Humalog®</brief_title>
	<detailed_description>Pfizer announce October 2007 would stop marketing Exubera® . At time recruitment study , A2171035 place hold . Nektar , company Pfizer license Exubera® , announce April 9 , 2008 stop search new marketing partner . Accordingly , commercial availability Exubera® . As result , study A2171035 terminate May 12 , 2008 . Neither safety efficacy reason cause study termination .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diabetes mellitus Type 1 Severe Asthma , severe Chronic Obstructive Pulmonary Disease ( COPD ) Smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>